Facebook
Twitter
LinkedIn
ForwardNovel Local Therapy for Recurrent Disease
It is imperative that our HNSCC medical care team across specialties professional remain current in the state-of-the-art techniques (Knowledge). There are many ongoing advances in patient safety in the context of immunotherapy, targeted therapy, surgery and RT for treatments for recurrent HNSCC (knowledge). Failure to stay informed leads to lower quality of care for these challenging care paradigms by practicing clinicians (competence). This panel is comprised of the leading experts in each of these arenas. They will share the latest research and practices along with practical case vignettes.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe the latest trials and research findings to change their practice patterns to support best practices in immunotherapy, for treatments for recurrent HNSCC.
- Describe the latest trials and research findings to change their practice patterns to support best practices in targeted therapy, for treatments for recurrent HNSCC.
- Describe the latest trials and research findings to change their practice patterns to support best practices in surgical approaches for recurrent HNSCC.
- Describe the latest trials and research findings to change their practice patterns to support best practices in radiation therapy, for treatments for recurrent HNSCCC.
Robert Haddad, MD, is employed by Dana-Farber Cancer Institute and has no financial relationships with a commercial interest.
Sana Karam, MD, PhD, is employed by the University of Colorado and receives research funding from Amgen and Genentech.
Young Kim, MD, PhD, is employed by Regeneron and receives compensation from Johns Hopkins, SOM and NIH.
Luc Morris, MD, FACS, is employed by Memorial Sloan Kettering Cancer Center and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.